The 5-year results of the Stratified Cancer Active Surveillance programme for men with prostate cancer.

ABSTRACT:

Objectives

To report 5-year outcomes from the STRATified CANcer Surveillance (STRATCANS) programme based on progression risks using National Institute for Health and Clinical Excellence (NICE) Cambridge Prognostic Group (CPG) at diagnosis, prostate specific antigen density and magnetic resonance imaging (MRI) visibility.

Patients and methods

Men with CPG1 and CPG2 disease selecting active surveillance (AS) were included into STRATCANS and allocated to one of three increasing follow-up intensities. Outcome measures were: (i) treatment for CPG≥3 progression (main outcome), (ii) any treatment, (iii) conversion to watchful waiting (WW), (iv) patient self-attrition, and (v) mortality.

Results

A total of 297 men (median age 66.0 years) were reviewed. The median (interquarti

SUBMITTER: Gnanapragasam VJ 

PROVIDER: S-EPMC11975195 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature